Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients
A Randomized, Double-Blind, Placebo-Controlled Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients When Added to Standard of Care
Sponsor: Nutrasource Pharmaceutical and Nutraceutical Services, Inc.
A NA clinical study on Non Alcoholic Fatty Liver, this trial is completed. The trial is conducted by Nutrasource Pharmaceutical and Nutraceutical Services, Inc. and has accumulated 8 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Mar 2022 — Jul 2024 [monthly]
Completed NA
-
Jan 2021 — Mar 2022 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 3 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
May 2017 — May 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — May 2017 [monthly]
Recruiting NA
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Nutrasource Pharmaceutical and Nutraceutical Services, Inc.
- Pronova BioPharma
For direct contact, visit the study record on ClinicalTrials.gov .